ClinicalTrials.gg
Active, not recruitingNCT05575037MARINERUpdated Nov 13, 2026Results posted

Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease

A Phase 2 interventional study of Dupilumab in Nasal Polyps, Asthma, Aspirin-Induced and Aspirin-Exacerbated Respiratory Disease, sponsored by Brigham and Women's Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Brigham and Women's Hospital · Phase 2, Interventional, and Treatment

How we know · 6 judgments

Updated Nov 13, 2026Results postedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing dupilumab in Nasal Polyps — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Nasal Polyps.

Enrollment
13th of 16
17 · median 45
Started
2023
with 2 others
Phase 2
2 of 16
none open now
Registered
9th of 16
by date
Lead sponsor
1 of 16
Brigham and Women's Hospital

Among the 16 studies testing dupilumab in Nasal Polyps, this one is the 13th largest by enrollment, is one of 3 that started in 2023, is one of 2 in phase 2, and was the 9th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

4 of the 16 studies testing dupilumab in Nasal Polyps are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing dupilumab in Nasal Polyps, or all of them as a file.
02

Study summary

The overall aim of the study is to determine the clinical efficacy and mechanisms of action of anti-IL-4a (dupilumab) as treatment for patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) and Aspirin-Exacerbated Respiratory Disease (AERD).

Read the detailed description

The protocol involves an 8-week study of dupilumab in patients with CRSwNP and/or AERD. Participants will have 4 total doses of dupilumab administered, with each dose administered every 2 weeks. There will be full clinical assessments and biospecimen collections at Baseline (Visit 1), Week 2 (Visit 2), and Week 8 (Visit 3).

03

Conditions studied

  • Nasal Polyps
  • Asthma, Aspirin-Induced
  • Aspirin-Exacerbated Respiratory Disease
  • Aspirin-Sensitive Asthma With Nasal Polyps

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. History of AERD, defined as meeting the diagnostic triad with:

    1. History of physician-diagnosed asthma and
    2. History of physician-diagnosed nasal polyposis and
    3. History of pathognomonic reactions to aspirin or other nonselective COX inhibitors.
  2. Visible nasal polyps bilaterally on otoscope physical exam at the time of screening.
  3. Evidence of sense of smell impairment, with a University of Pennsylvania Smell Identification Test (UPSIT) score of \<34.
  4. Stable asthma (no burst for at least 4 weeks prior to Visit 1, and no hospitalizations or ER visits for asthma for at least the prior 3 months).
  5. Consistent (daily) use of an intranasal steroid for at least 4 weeks prior to Screening.
  6. No current smoking (not more than one instance of smoking in the last 3 months).
  7. For females: Practicing FDA-approved methods of for the duration of the study. Female participants of must have a negative pregnancy test upon study entry.

Key Exclusion Criteria:

  1. Use of drugs within 12 weeks of Screening.
  2. Use of any biologic agent within 4 months prior to Screening.
  3. Use of systemic (enteral or injected) glucocorticoids within 4 weeks prior to Screening.
  4. History of any sinonasal surgery within 4 months prior to Screening
  5. Current use of zileuton
  6. Current use of high-dose aspirin therapy (no more than 325 mg aspirin per day will be allowed)
  7. Pregnant, nursing, or planning to become pregnant

Note: Other inclusion and exclusion criteria apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Dupilumab

    Subjects will receive dupilumab (300mg every-other-week for 8 weeks).

    Drug: Dupilumab

Interventions

  • 8-week trial of dupilumab (an anti-IL-4a) in patients with AERD.

    Also known as: Dupilumab Prefilled Syringe [Dupixent]

06

What researchers measure

Primary outcomes

  1. Nasal Fluid Levels of LTE4

    The nasal fluid levels of LTE4 will be measured at week 8 and will serve as a surrogate biomarker of respiratory mast cell activation or burden.

    Time frame: At Week 8 (Visit 3)

Secondary outcomes

  1. Nasal Fluid Levels of Albumin

    The nasal fluid levels of albumin will be measured at week 8 and serve as a surrogate biomarker of nasal epithelial cell integrity.

    Time frame: At Week 8 (Visit 3)

  2. Sense of Smell - University of Pennsylvania Smell Identification Test (UPSIT)

    Patients' sense of smell will be assessed at week 8 using the UPSIT. The UPSIT scale goes from 0 to 40, with 0 being worse (no scents identified) and 40 being best (all scents identified)

    Time frame: At Week 8 (Visit 3)

  3. Rhinoscopic Total Polyp Score (TPS)

    The extent of patients' nasal polyps will be assessed at week 8 using a TPS. The TPS scale goes from 0 (no polyps) to 8 (large polyps bilaterally), with 0 being best and 8 being worst.

    Time frame: At Week 8 (Visit 3)

  4. Peak Nasal Inspiratory Flow (PNIF)

    Patients' nasal congestion will be assessed at week 8 by a PNIF. PNIF goes from 0 mL (no airflow) to 500 mL of airflow, with 0 being worst.

    Time frame: At Week 8 (Visit 3)

  5. Quality of Life - 22-Item Sino-Nasal Outcome Test (SNOT-22)

    Quality of life will be assessed at week 8 with a SNOT-22. For the SNOT-22, the scores range from 0 (no symptoms, excellent disease control) to 110 (maximum sinus symptoms, poor disease control).

    Time frame: At Week 8 (Visit 3)

  6. Lung Function - Forced Expiratory Volume 1 (FEV1)

    Patients' lung function will be assessed at week 8 with an FEV1.

    Time frame: At Week 8 (Visit 3)

  7. Asthma Control - Asthma Control Questionnaire-6 (ACQ-6)

    Asthma control will be measured at week 8 with an ACQ-6. For the ACQ-6, scores ranging from 0 (well-controlled) to 6 (extremely poorly-controlled). A lower score indicates better asthma control.

    Time frame: At Week 8 (Visit 3)

  8. Number of Treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs) Leading to Study Drug Discontinuation

    Safety will be measured by the number of treatment-related AEs and SAEs leading to dupilumab discontinuation.

    Time frame: At Week 8 (Visit 3)

Other outcomes

  1. Change in Sense of Smell - University of Pennsylvania Smell Identification Test (UPSIT)

    Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in UPSIT. The UPSIT scale goes from 0 to 40, with 0 being worse (no scents identified) and 40 being best (all scents identified)

    Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

  2. Change in Rhinoscopic Total Polyp Score (TPS)

    Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in TPS. The TPS scale goes from 0 (no polyps) to 8 (large polyps bilaterally), with 0 being best and 8 being worst.

    Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

  3. Change in Peak Nasal Inspiratory Flow (PNIF)

    Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in PNIF. PNIF goes from 0 mL (no airflow) to 500 mL of airflow, with 0 being worst.

    Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

  4. Change in 22-Item Sino-Nasal Outcome Test (SNOT-22)

    Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in SNOT-22. For the SNOT-22, the scores range from 0 (no symptoms, excellent disease control) to 110 (maximum sinus symptoms, poor disease control).

    Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

  5. Change in Lung Function - Forced Expiratory Volume 1 (FEV1)

    Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in FEV1.

    Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

  6. Change in Asthma Control - Asthma Control Questionnaire-6 (ACQ-6)

    Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in ACQ-6. For the ACQ-6, scores ranging from 0 (well-controlled) to 6 (extremely poorly-controlled). A lower score indicates better asthma control.

    Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

  7. Change in Nasal Fluid Levels of Eicosanoids

    Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid eicosanoid levels.

    Time frame: weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

  8. Change in Nasal Fluid Levels of Albumin

    Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid albumin levels.

    Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

  9. Change in Urinary Levels of Eicosanoids

    Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in urinary eicosanoid levels.

    Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

  10. Change in Serum Tryptase

    Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in serum tryptase levels.

    Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

  11. Change in IgE Levels

    Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid and plasma levels of IgE.

    Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

  12. Change in Eosinophilic Cationic Protein (ECP)

    Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid levels of ECP.

    Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

07

Results

Posted Nov 13, 2026

Participant flow

Participant flow — Overall Study
MilestoneDupilumab
Started17
Completed17
Not completed0

Outcome measures

PrimaryNasal Fluid Levels of LTE4

The nasal fluid levels of LTE4 will be measured at week 8 and will serve as a surrogate biomarker of respiratory mast cell activation or burden.

Time frame:
At Week 8 (Visit 3)
Reported as:
Mean · ng per mg creatinine
Nasal Fluid Levels of LTE4
ng per mg creatinineDupilumab
Nasal Fluid Levels of LTE40.01100 ± 0.01173
SecondaryNasal Fluid Levels of Albumin

The nasal fluid levels of albumin will be measured at week 8 and serve as a surrogate biomarker of nasal epithelial cell integrity.

Time frame:
At Week 8 (Visit 3)

Results for this outcome have not been posted.

SecondarySense of Smell - University of Pennsylvania Smell Identification Test (UPSIT)

Patients' sense of smell will be assessed at week 8 using the UPSIT. The UPSIT scale goes from 0 to 40, with 0 being worse (no scents identified) and 40 being best (all scents identified)

Time frame:
At Week 8 (Visit 3)
Reported as:
Mean · Smell test score
Sense of Smell - University of Pennsylvania Smell Identification Test (UPSIT)
Smell test scoreDupilumab
Sense of Smell - University of Pennsylvania Smell Identification Test (UPSIT)26.1 ± 10.6
SecondaryRhinoscopic Total Polyp Score (TPS)

The extent of patients' nasal polyps will be assessed at week 8 using a TPS. The TPS scale goes from 0 (no polyps) to 8 (large polyps bilaterally), with 0 being best and 8 being worst.

Time frame:
At Week 8 (Visit 3)
Reported as:
Mean · Score out of 8
Rhinoscopic Total Polyp Score (TPS)
Score out of 8Dupilumab
Rhinoscopic Total Polyp Score (TPS)2.9 ± 2.5
SecondaryPeak Nasal Inspiratory Flow (PNIF)

Patients' nasal congestion will be assessed at week 8 by a PNIF. PNIF goes from 0 mL (no airflow) to 500 mL of airflow, with 0 being worst.

Time frame:
At Week 8 (Visit 3)
Reported as:
Mean · Nasal flow in mL
Peak Nasal Inspiratory Flow (PNIF)
Nasal flow in mLDupilumab
Peak Nasal Inspiratory Flow (PNIF)124.8 ± 46.2
SecondaryQuality of Life - 22-Item Sino-Nasal Outcome Test (SNOT-22)

Quality of life will be assessed at week 8 with a SNOT-22. For the SNOT-22, the scores range from 0 (no symptoms, excellent disease control) to 110 (maximum sinus symptoms, poor disease control).

Time frame:
At Week 8 (Visit 3)
Reported as:
Mean · Score out of 110
Quality of Life - 22-Item Sino-Nasal Outcome Test (SNOT-22)
Score out of 110Dupilumab
Quality of Life - 22-Item Sino-Nasal Outcome Test (SNOT-22)17.6 ± 11.9
SecondaryLung Function - Forced Expiratory Volume 1 (FEV1)

Patients' lung function will be assessed at week 8 with an FEV1.

Time frame:
At Week 8 (Visit 3)
Reported as:
Mean · mL
Lung Function - Forced Expiratory Volume 1 (FEV1)
mLDupilumab
Lung Function - Forced Expiratory Volume 1 (FEV1)2.7 ± 0.7
SecondaryAsthma Control - Asthma Control Questionnaire-6 (ACQ-6)

Asthma control will be measured at week 8 with an ACQ-6. For the ACQ-6, scores ranging from 0 (well-controlled) to 6 (extremely poorly-controlled). A lower score indicates better asthma control.

Time frame:
At Week 8 (Visit 3)
Reported as:
Mean · Score out of 6
Asthma Control - Asthma Control Questionnaire-6 (ACQ-6)
Score out of 6Dupilumab
Asthma Control - Asthma Control Questionnaire-6 (ACQ-6)0.4 ± 0.4
SecondaryNumber of Treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs) Leading to Study Drug Discontinuation

Safety will be measured by the number of treatment-related AEs and SAEs leading to dupilumab discontinuation.

Time frame:
At Week 8 (Visit 3)
Reported as:
Count of participants · Participants
Number of Treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs) Leading to Study Drug Discontinuation
ParticipantsDupilumab
Number of Treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs) Leading to Study Drug Discontinuation0
Other pre-specifiedChange in Sense of Smell - University of Pennsylvania Smell Identification Test (UPSIT)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in UPSIT. The UPSIT scale goes from 0 to 40, with 0 being worse (no scents identified) and 40 being best (all scents identified)

Time frame:
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Results for this outcome have not been posted.

Other pre-specifiedChange in Rhinoscopic Total Polyp Score (TPS)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in TPS. The TPS scale goes from 0 (no polyps) to 8 (large polyps bilaterally), with 0 being best and 8 being worst.

Time frame:
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Results for this outcome have not been posted.

Other pre-specifiedChange in Peak Nasal Inspiratory Flow (PNIF)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in PNIF. PNIF goes from 0 mL (no airflow) to 500 mL of airflow, with 0 being worst.

Time frame:
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Results for this outcome have not been posted.

Other pre-specifiedChange in 22-Item Sino-Nasal Outcome Test (SNOT-22)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in SNOT-22. For the SNOT-22, the scores range from 0 (no symptoms, excellent disease control) to 110 (maximum sinus symptoms, poor disease control).

Time frame:
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Results for this outcome have not been posted.

Other pre-specifiedChange in Lung Function - Forced Expiratory Volume 1 (FEV1)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in FEV1.

Time frame:
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Results for this outcome have not been posted.

Other pre-specifiedChange in Asthma Control - Asthma Control Questionnaire-6 (ACQ-6)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in ACQ-6. For the ACQ-6, scores ranging from 0 (well-controlled) to 6 (extremely poorly-controlled). A lower score indicates better asthma control.

Time frame:
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Results for this outcome have not been posted.

Other pre-specifiedChange in Nasal Fluid Levels of Eicosanoids

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid eicosanoid levels.

Time frame:
weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Results for this outcome have not been posted.

Other pre-specifiedChange in Nasal Fluid Levels of Albumin

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid albumin levels.

Time frame:
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Results for this outcome have not been posted.

Other pre-specifiedChange in Urinary Levels of Eicosanoids

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in urinary eicosanoid levels.

Time frame:
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Results for this outcome have not been posted.

Other pre-specifiedChange in Serum Tryptase

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in serum tryptase levels.

Time frame:
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Results for this outcome have not been posted.

Other pre-specifiedChange in IgE Levels

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid and plasma levels of IgE.

Time frame:
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Results for this outcome have not been posted.

Other pre-specifiedChange in Eosinophilic Cationic Protein (ECP)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid levels of ECP.

Time frame:
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Results for this outcome have not been posted.

Adverse events

Collected over From enrollment until end of study, up to 8 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dupilumab0/17 (0%)0/17 (0%)0/17 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Dupilumab
Mean51 ± 17
Sex: Female, Male
Sex: Female, Male(Participants)Dupilumab
Female10
Male7
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dupilumab
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White16
More than one race0
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dupilumab
Hispanic or Latino1
Not Hispanic or Latino16
Unknown or Not Reported0
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Apr 2026, 32 months.

Results were first posted in Nov 2026, 6 months after primary completion.

Of 24 phase 2 interventional studies under Nasal Polyps, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 32. This study's 32 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2022
First posted
Oct 12, 2022
StartActual
Aug 1, 2023
Primary completionActual
Apr 30, 2026
CompletionEst.
Dec 30, 2026
Results first posted
Nov 13, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 13, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedNasal fluid levelsFluid Levels of LTE4Time frame: At Week 8 (Visit 3)
Nov 13, 2026
Secondary outcomes
15 edited
What changed in the outcomes
  • EditedNasal fluid levelsFluid Levels of albuminAlbuminTime frame: At Week 8 (Visit 3)
  • EditedSense of smellSmell - University of Pennsylvania Smell Identification Test (UPSIT)Time frame: At Week 8 (Visit 3)
  • EditedQuality of lifeLife - 22-Item Sino-Nasal Outcome Test (SNOT-22)Time frame: At Week 8 (Visit 3)
  • EditedLung functionFunction - Forced Expiratory Volume 1 (FEV1)Time frame: At Week 8 (Visit 3)
  • EditedAsthma controlControl - Asthma Control Questionnaire-6 (ACQ-6)Time frame: At Week 8 (Visit 3)
  • EditedNumber of treatmentTreatment-related adverse eventsAdverse Events (AEs) and serious adverse eventsSerious Adverse Events (SAEs) leadingLeading to study drug discontinuationStudy Drug DiscontinuationTime frame: At Week 8 (Visit 3)
  • Editedother outcomeChange in senseSense of smellSmell - University of Pennsylvania Smell Identification Test (UPSIT)Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
  • Editedother outcomeChange in lung functionLung Function - Forced Expiratory Volume 1 (FEV1)Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
  • Editedother outcomeChange in Asthma controlControl - Asthma Control Questionnaire-6 (ACQ-6)Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
  • Editedother outcomeChange in Nasal fluid levelsFluid Levels of eicosanoidsEicosanoidsTime frame: weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
  • Editedother outcomeChange in Nasal fluid levelsFluid Levels of albuminAlbuminTime frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
  • Editedother outcomeChange in urinary levelsUrinary Levels of eicosanoidsEicosanoidsTime frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
  • Editedother outcomeChange in serum tryptaseSerum TryptaseTime frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
  • Editedother outcomeChange in IgE levelsLevelsTime frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
  • Editedother outcomeChange in eosinophilic cationic proteinEosinophilic Cationic Protein (ECP)Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedNasal fluid levelsFluid Levels of LTE4Time frame: At Week 8 (Visit 3)
    Secondary outcomes 15 edited
    What changed in the outcomes
    • EditedNasal fluid levelsFluid Levels of albuminAlbuminTime frame: At Week 8 (Visit 3)
    • EditedSense of smellSmell - University of Pennsylvania Smell Identification Test (UPSIT)Time frame: At Week 8 (Visit 3)
    • EditedQuality of lifeLife - 22-Item Sino-Nasal Outcome Test (SNOT-22)Time frame: At Week 8 (Visit 3)
    • EditedLung functionFunction - Forced Expiratory Volume 1 (FEV1)Time frame: At Week 8 (Visit 3)
    • EditedAsthma controlControl - Asthma Control Questionnaire-6 (ACQ-6)Time frame: At Week 8 (Visit 3)
    • EditedNumber of treatmentTreatment-related adverse eventsAdverse Events (AEs) and serious adverse eventsSerious Adverse Events (SAEs) leadingLeading to study drug discontinuationStudy Drug DiscontinuationTime frame: At Week 8 (Visit 3)
    • Editedother outcomeChange in senseSense of smellSmell - University of Pennsylvania Smell Identification Test (UPSIT)Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
    • Editedother outcomeChange in lung functionLung Function - Forced Expiratory Volume 1 (FEV1)Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
    • Editedother outcomeChange in Asthma controlControl - Asthma Control Questionnaire-6 (ACQ-6)Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
    • Editedother outcomeChange in Nasal fluid levelsFluid Levels of eicosanoidsEicosanoidsTime frame: weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
    • Editedother outcomeChange in Nasal fluid levelsFluid Levels of albuminAlbuminTime frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
    • Editedother outcomeChange in urinary levelsUrinary Levels of eicosanoidsEicosanoidsTime frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
    • Editedother outcomeChange in serum tryptaseSerum TryptaseTime frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
    • Editedother outcomeChange in IgE levelsLevelsTime frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
    • Editedother outcomeChange in eosinophilic cationic proteinEosinophilic Cationic Protein (ECP)Time frame: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
    + 1 other change: responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05575037
Responsible party
Tanya Laidlaw, MD (Professor of Medicine, Brigham and Women's Hospital) — Principal investigator
First posted
Oct 12, 2022
Start date
Aug 1, 2023
Primary completion
Apr 30, 2026
Completion
Dec 30, 2026 (estimated)
Results posted
Nov 13, 2026
Last update
Nov 13, 2026

Study contacts

Tanya M Laidlaw, MD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion